ÂÜÀòÂÒÂ×

Clay Cohorn has a comprehensive work experience in the healthcare industry. Clay is currently serving as the Vice President of Clinical Affairs at Osteal Therapeutics since July 2022. Prior to this role, Clay worked at Abbott as the Director of Clinical Research for their global Cardiac Rhythm Management portfolio from May 2016 to July 2022. During their tenure at Abbott, they successfully obtained global regulatory authority approvals for the first cardiac resynchronization therapy device with Multi-Point Pacing.

Before joining Abbott, Clay held the role of Senior Manager of Clinical Trial Reimbursement at St. Jude Medical from June 2014 to May 2016. Clay achieved the company's first Medicare national IDE clinical trial coverage approval and developed a Clinical Trial Reimbursement education program to train clinical trial partners on the IDE billing and reimbursement process.

Their earlier experience includes their role as the Manager of Clinical Studies, Vascular Intervention at BIOTRONIK from December 2009 to June 2014. Clay managed a team responsible for overseeing clinical studies, including protocol development, training, study reimbursement, clinical data reporting, and regulatory submissions. Clay also served as a Clinical Studies Engineer at BIOTRONIK from November 2005 to December 2009, where they successfully gained FDA approval for an investigational device feature for implantable defibrillators.

Prior to their time at BIOTRONIK, Clay worked at Cyberonics as a Clinical Engineer from January 2003 to November 2005. In this role, they provided clinical and technical support during device implants and follow-up procedures. Clay also conducted product training programs and educated healthcare professionals on the use of a vagal nerve stimulator for the treatment of epilepsy and depression.

Overall, Clay Cohorn has extensive experience in clinical research, reimbursement, and regulatory affairs within the healthcare industry.

Clay Cohorn completed their undergraduate education from 1998 to 2002 at Texas A&M University. During this time, they pursued a Bachelor of Science degree in Biomedical Engineering.